Live tape
Top 8, mentions 7d6,397META1,684 mentions▲ +0.06GOOGL1,241 mentions▲ +0.03NVDA822 mentions▲ +0.09TSLA607 mentions▲ +0.05MSFT549 mentions▲ +0.06AMZN528 mentions▲ +0.04SPY501 mentions▲ +0.04AAPL465 mentions▲ +0.06

Equity · Healthcare

TBPH

NASDAQ

Theravance Biopharma, Inc.

$16.94 −0.24% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Jul 17, 2026
Price · Chart
Our own end-of-day closes 11 sessions
$17.05 $16.85 2 Jul 17 Jul

The line runs $17 on 2 July through $16.94 on 17 July, on a scale from $16.85 to $17.05. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of TBPH over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 11 sessions over that window: $17 on 2 July 2026 through $16.94 on 17 July 2026.

Market cap $879.5M
P/E (TTM) 16.8
52-week range $11 – $21
Avg volume 244.2K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Jul 17, 2026

TBPH insider trades

SEC Form 4 · last 90 days · newest reported trade 15 Sep 2026
Open-market buys 0
Open-market sells 1
Net sold $227K
Non-trade filings 15
Date Insider Type Shares Value
15 Sep 2026 Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS Sell 13,314 $227K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
23 Sep 2026 Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS Other 213,476
23 Sep 2026 GRAY SUSANNAH Director Other 48,146
23 Sep 2026 Grimaud Brett A. SVP, GEN COUNSEL AND SECRETARY Other 355,168
23 Sep 2026 MITCHELL DEAN J Director Other 97,213
23 Sep 2026 Miller Aine SVP, DEV & HEAD OF IRE OFFICE Other 189,826
23 Sep 2026 O'Connor Donal Director Other 80,213
23 Sep 2026 PAKIANATHAN DEEPIKA Director Other 64,074
23 Sep 2026 Sawaf Aziz SVP & CHIEF FINANCIAL OFFICER Other 336,841
23 Sep 2026 Smaldone Alsup Laurie Director Other 80,989
23 Sep 2026 Winningham Rick E CHIEF EXECUTIVE OFFICER Other 1,726,989
20 Aug 2026 Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS Tax withheld 5,667 $96K
20 Aug 2026 Grimaud Brett A. SVP, GEN COUNSEL AND SECRETARY Tax withheld 7,952 $135K

Showing the 12 most recent of 15 compensation filings in this window. The figures above count all of them.

TBPH reported financials

SEC EDGAR XBRL

TBPH reported revenue of $107.5M for the fiscal year ended 31 Dec 2025. Net income over the same period was $105.9M.

Figure Reported Period
Revenue $107.5M 31 Dec 2025 fiscal year
Net income $105.9M 31 Dec 2025 fiscal year
Diluted EPS $2.06 31 Dec 2025 fiscal year
Total assets $469.8M 30 Jun 2026 at period end
Total equity $289.7M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

TBPH earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.11 —
31 Mar 2026 Q1 2026 $-0.10 —
31 Dec 2025 FY 2025 $1.15 —
30 Sep 2025 FY 2025 $0.07 —
30 Jun 2025 FY 2025 $1.08 —
31 Mar 2025 Q1 2025 $-0.27 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

TBPH institutional holders

SEC Form 13F

9 of the 45 institutional funds we track reported a TBPH position for the quarter ended 30 Jun 2026 — a combined $59.9M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Two Sigma Investments Held (±25%) −2.6% shares 1,225,587 $20.8M
D. E. Shaw & Co. Held (±25%) +24.2% shares 1,185,390 $20.2M
Citadel Advisors Added +488.5% shares 506,668 $8.6M
Marshall Wace Held (±25%) +18.8% shares 188,748 $3.2M
Renaissance Technologies Held (±25%) +20.6% shares 154,318 $2.6M
Millennium Management New position 115,403 $2.0M
Tudor Investment Corp Trimmed −49.7% shares 60,425 $1.0M
AQR Capital Management Added +74.8% shares 47,820 $813K
Man Group Held (±25%) −3.5% shares 40,613 $690K

Source: SEC EDGAR 13F filings

TBPH fails-to-deliver

SEC CNS data

On 10 Sep 2026, 10 shares of TBPH failed to deliver (about $171).

Settlement date Shares failed Notional % of shares out
10 Sep 2026 10 $171 <0.001%
27 Aug 2026 3 $51 <0.001%
20 Aug 2026 12 $204 <0.001%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in TBPH

STOCK Act disclosures

The most recent congressional trade disclosed in TBPH is a sale by George Whitesides (house, CA), dated 24 Mar 2025.

Date Member Type Amount
24 Mar 2025 filed 23 Apr 2025 George Whitesides house · Democrat–CA Sale $15K–$50K

Source: U.S. House of Representatives financial disclosures